CONTACT INFO

SCHWARTZ MSL HOMEPAGE

PRx

October 2008

Marketing in Turbulent Markets

A colleague and I recently attended the Massachusetts Biotechnology Council event, “Marketing in Turbulent Markets: Creative Strategies for Marketing Challenges”—something that everyone can definitely relate to these days. For anyone who has never attended an MBC event, I highly recommend them—a great way to meet fellow marketing folks, network, catch up on what’s going on in the industry and share best practices.

The lead speaker, Nancy Levy, founder and managing partner of BioHealth Management, LLC, a commercial strategy and business development consulting firm, gave a great overview on how to “Create the Buzz without the Bee.” Levy talked about the evolution of the four P’s of marketing: product, price, place and promotion are being replaced, or, at very least, supplemented with personalization, participation and peer-to-peer.

What this boils down to is knowing who your customer is and tailoring for that audience; involving your customers from around the globe and really listening to what they want, need and their thoughts about your brand; and using social and professional networks to spread a message—advocacy groups, patient groups, research organizations, etc.

Biotech is unlike most industries because the “product” is intangible. Typically, the product is innovation and the ability to do something. This presents inherent marketing challenges that underscore the importance of personalization, participation and peer-to-peer marketing efforts.

This marketing mantra definitely holds true for public relations. We advise our clients to focus messaging on the innovation and benefits, rather than simply features of the products. This is what interests customers and generate sales.

In times of a tumultuous economy, it becomes even more critical to stretch marketing budgets and reach as many potential customers as possible. PR is a marketing avenue that works hand-in-hand with the three Ps. Because PR is cost-effective, strategic and easily adapted to communicate with various audiences, it presents an opportunity to build your brand, communicate with customers, and engage key opinion leaders without breaking the bank.

If you are trying to decide what to put in your marketing mix that will be the most effective, you are putting yourself at a disservice if your PR activities go black. Dollar for dollar, PR is more cost effective than advertising and there are countless studies that underscore this.

For those companies thinking they can’t afford to put marketing dollars to PR, consider this:, it’s a risky approach; if even just one competitor pushes ahead with PR and is the one to get the exposure, when the tides turn, who do you think the public will remember—the company who has been radio silent for the past months or the company that they have been reading about?

All in all, it was an informative, timely meeting and really hammers home the message that smart marketing can help take us through these turbulent times. I am definitely planning to attend upcoming Mass Biotech Council meetings and will report on what I learn.

 

 

 

Tags: Biotech PR, Healthcare PR, Mass Biotech Council

Posted by Lauren Arnold on October 30, 2008 at 10:35 AM
| TrackBack (0)

PR Works for Clinical Trial Patient Recruitment

As PRWeek reports, public relations can be a cost-effective, powerful and efficient way to recruit patients for a clinical trial. That’s what EnteroMedics found when they hired us for a 7-month project to help accelerate patient recruitment for its EMPOWER Study. EnteroMedics makes an implantable device that delivers VBLOC Therapy to treat obesity.

The company needed to enroll up to 300 patients by August. Beginning in January, our team executed a PR campaign targeted at national media and the 13 U.S. markets with clinical sites. As a result of the PR efforts alone, more than 2000 patients were screened and of those, 9% or 190 were prequalified for the study. The news stories on the study, both on the national and local level significantly boosted awareness and helped to drive inquiries into the website and the call center. For instance, after a front page story appeared in the San Francisco Chronicle, web hits increased 350% and after a segment on Good Morning America traffic to the site increased 600%.

We’ve been doing this type of work for some time for clients. In fact, one of the first clinical trial recruitment campaigns we executed was for Gynecare (now Ethicon/J&J) for its uterine balloon therapy for menorrhagia. For that campaign, a segment on GMA with the lead clinical investigator stimulated a flood of phone calls to the call center—enough to fill the study. We also managed a patient recruitment campaign in 20 markets for Northstar Neuroscience for its clinical trial of cortical stimulation for stroke and just wrapped a project for client BioMS, helping to recruit patients for a Phase III trial of an experimental Multiple Sclerosis drug, Dirucotide. The goal, achieved in part with our PR assistance—recruit 510 patients for 68 U.S. clinical sites.

Tags: clinical trial recruitment, EnteroMedics, healthcare PR, medical device PR, obesity device

Posted by Helen Shik on October 28, 2008 at 11:59 AM
| TrackBack (0)

Sign up here to receive our PRx Newsletter, Schwartz MSL's quarterly healthcare publication.
 Email (required) *
 
 First Name
 
 Last Name
 
 Company